The Effect of Curcumin on Serum Copper and Zinc and Zn/Cu Ratio in Individuals with Metabolic Syndrome: A Double-Blind Clinical Trial.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc and Copper (Supplement), published as a randomized controlled trial.

The aim of this study was to investigate the effects of curcumin on serum copper (Cu), zinc (Zn), and Zn/Cu ratio levels in patients with metabolic syndrome.

Why It Was Studied

Metabolic syndrome is a complex disorder with high socioeconomic costs and a high global prevalence.

The serum concentrations of some trace elements are higher in people with metabolic syndrome compared to normal individuals.

Who Took Part

The abstract describes 120 individuals taking part.

PubMed indexes the participants as adults and middle-aged adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.

Serum copper and zinc were measured before and after intervention.

What Was Measured

The subject headings attached to it are Antioxidants, Copper, Curcumin, Dietary Supplements, Fasting, Metabolic Syndrome and Zinc.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc and Copper (Supplement) in 120 individuals.

The publication is from 2019 (Journal of dietary supplements), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page and the Copper (Supplement) compound page, all human trials.